Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, issue.15, pp.4429-4463, 2007. ,
Prognostic markers in triple-negative breast cancer, Cancer, vol.109, issue.1, pp.25-32, 2007. ,
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity, Breast Cancer Res Treat, vol.116, issue.2, pp.317-345, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00478271
Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?, Cancer J, vol.16, issue.1, pp.23-32, 2010. ,
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients, Endocr Rev, vol.13, issue.1, pp.3-17, 1992. ,
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy, Expert Rev Mol Diagn, vol.8, issue.4, pp.417-451, 2008. ,
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles, Breast Cancer Res, vol.13, issue.6, p.133, 2011. ,
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations, Mod Pathol, vol.18, issue.8, pp.1027-1060, 2005. ,
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers, BMC Cancer, vol.8, p.309, 2008. ,
Protein expression, gene amplification, and mutational analysis of EGFR in triplenegative breast cancer. Breast Cancer, 2012. ,
Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features, Histol Histopathol, vol.27, issue.6, pp.785-92, 2012. ,
EGFR expression and gene copy number in triple-negative breast carcinoma, Cancer Genet Cytogenet, vol.203, issue.2, pp.222-231, 2010. ,
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer, Breast Cancer Res, vol.13, issue.6, p.224, 2011. ,
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma, Cancer Res, vol.65, issue.7, pp.2554-2563, 2005. ,
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality, Int J Cancer, vol.126, issue.5, pp.1121-1152, 2010. ,
PIK3CA mutation associates with improved outcome in breast cancer, Clin Cancer Res, vol.15, issue.16, pp.5049-59, 2009. ,
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer, Mol Cancer Ther, vol.10, issue.6, pp.1093-101, 2011. ,
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer, Clin Cancer Res, vol.15, issue.7, pp.2472-2480, 2009. ,
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Res, vol.13, issue.1, p.15, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01825781
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer, Int J Biol Markers, vol.21, issue.1, pp.20-29, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-01823855
Meeting highlights: international expert consensus on the primary therapy of early breast cancer, Ann Oncol, vol.16, issue.10, pp.1569-83, 2005. ,
Adjuvant early breast cancer systemic therapies according to daily used technologies, Crit Rev Oncol Hematol, 2011. ,
Urokinasetype plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression, Am J Clin Pathol, vol.128, issue.3, pp.404-417, 2007. ,
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant! St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial, Ann Oncol, vol.20, issue.2, pp.258-64, 2009. ,
Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations, Br J Cancer, vol.110, issue.4, pp.1045-52, 2014. ,
Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC), Cancer Chemother Pharmacol, vol.68, issue.3, pp.753-61, 2011. ,
The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.486, issue.7403, pp.395-404, 2012. ,
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer, Mod Pathol, vol.27, issue.9, pp.1212-1234, 2014. ,
High frequency of mutations of the PIK3CA gene in human cancers, Science, vol.304, issue.5670, p.554, 2004. ,
Analysis of PIK3CA mutations in breast cancer subtypes, Appl Immunohistochem Mol Morphol, vol.22, issue.1, pp.50-56, 2014. ,
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer, Cancer Res, vol.68, issue.15, pp.6084-91, 2008. ,
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups, Breast Cancer Res, vol.14, issue.1, p.28, 2012. ,
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms, Proc Natl Acad Sci, vol.105, issue.7, pp.2652-2659, 2008. ,
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis, OncoTargets and therapy, vol.7, pp.543-52, 2014. ,
Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer, Ann Oncol, vol.25, issue.10, pp.1973-1982, 2014. ,
Sequence analysis of mutations and translocations across breast cancer subtypes, Nature, vol.486, issue.7403, pp.405-414, 2012. ,
Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer, Med Oncol, vol.31, issue.1, p.801, 2014. ,
Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer, Histopathology, vol.61, issue.4, pp.652-661, 2012. ,
High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors, Cancer, vol.121, pp.3422-3429, 2015. ,